Patent · US Expired

Trova fowl pox virus recombinants comprising heterologous inserts

US5766599A · kind A · utility

18Cited by
6References
14Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJun 1, 1995
Grant dateJun 16, 1998
Priority date
Expiry dateJun 1, 2015

Classification

  • Technology area (CPC Y)Emerging Cross-Sectional Technologies
  • CPC primaryY10S530/826
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

What is described is a modified vector, such as a recombinant poxvirus, particularly recombinant vaccinia virus, having enhanced safety. The modified recombinant virus has nonessential virus-encoded genetic functions inactivated therein so that virus has attenuated virulence. In one embodiment, the genetic functions are inactivated by deleting an open reading frame encoding a virulence factor. In another embodiment, the genetic functions are inactivated by insertional inactivation of an open reading frame encoding a virulence factor. What is also described is a vaccine containing the modified recombinant virus having nonessential virus-encoded genetic functions inactivated therein so that the vaccine has an increased level of safety compared to known recombinant virus vaccines.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.